| Literature DB >> 32563380 |
A Benjamin Srivastava1, John J Mariani2, Frances R Levin2.
Abstract
The treatment of opioid withdrawal is an important area of clinical concern when treating patients with chronic, non-cancer pain, patients with active opioid use disorder, and patients receiving medication for opioid use disorder. Current standards of care for medically supervised withdrawal include treatment with μ-opioid receptor agonists, (eg, methadone), partial agonists (eg, buprenorphine), and α2-adrenergic receptor agonists (eg, clonidine and lofexidine). Newer agents likewise exploit these pharmacological mechanisms, including tramadol (μ-opioid receptor agonism) and tizanidine (α2 agonism). Areas for future research include managing withdrawal in the context of stabilising patients with opioid use disorder to extended-release naltrexone, transitioning patients with opioid use disorder from methadone to buprenorphine, and tapering opioids in patients with chronic, non-cancer pain.Entities:
Mesh：
Substances：
Year: 2020 PMID： 32563380 PMCID： PMC7385662 DOI： 10.1016/S0140-6736(20)30852-7
Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321